Literature DB >> 21457926

Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy.

Akitaka Tsujikawa1, Yumiko Ojima, Kenji Yamashiro, Isao Nakata, Sotaro Ooto, Hiroshi Tamura, Hideo Nakanishi, Hisako Hayashi, Atsushi Otani, Nagahisa Yoshimura.   

Abstract

PURPOSE: To investigate the progression of vascular lesions of polypoidal choroidal vasculopathy (PCV) as viewed with indocyanine green angiography and the visual prognosis of these eyes.
DESIGN: Retrospective case study.
METHODS: We reviewed retrospectively the medical records of 88 consecutive patients (88 eyes) with PCV who had been examined with indocyanine green angiography for more than 2 years.
RESULTS: Depending on the initial area of the vascular lesion, eyes were divided into smaller PCV (baseline area of lesion being < 1 disc area [DA], n = 22) and larger PCV (baseline area of lesion being ≥ 1 DA, n = 66). In larger PCV, the mean area of the lesion progressed significantly from 6.49 ± 8.96 mm(2) to 16.27 ± 14.19 mm(2) (P < .0001) with marked deterioration of visual acuity (P < .0001) during follow-up. In contrast, smaller PCV often showed minimal progression of the lesion, only limited exudative change, and the eyes maintained their initially good vision to the final visit. Smaller PCV lesions rarely progressed to extensive PCV lesions. Severe vision-threatening complications (ie, suprachoroidal hemorrhage, vitreous hemorrhage, and tears of the retinal pigment epithelium) were seen only in eyes with larger PCV, and in studying single nucleotide polymorphisms A69S of ARMS2 genes, there was a significant difference in T allele frequency between individuals with smaller PCV and those with larger PCV (20.2% vs 79.8%; P = .0235).
CONCLUSIONS: PCV with small vascular lesions shows minimal progression and no vision-threatening complications, and these eyes often maintain good visual acuity for a long time.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21457926     DOI: 10.1016/j.ajo.2011.01.002

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  22 in total

1.  Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy.

Authors:  Hae Min Kang; Hyoung Jun Koh; Sung Chul Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-12-21       Impact factor: 3.117

2.  Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome.

Authors:  M Ho; E C F Lo; A L Young; D T L Liu
Journal:  Eye (Lond)       Date:  2014-09-26       Impact factor: 3.775

3.  Proteolytic Degradation and Inflammation Play Critical Roles in Polypoidal Choroidal Vasculopathy.

Authors:  Sandeep Kumar; Hiroyuki Nakashizuka; Alex Jones; Alyssia Lambert; Xuchen Zhao; Megan Shen; Mackenzie Parker; Shixian Wang; Zachary Berriochoa; Amrita Fnu; Stephanie VanBeuge; Patricia Chévez-Barrios; Mark Tso; Jon Rainier; Yingbin Fu
Journal:  Am J Pathol       Date:  2017-09-21       Impact factor: 4.307

4.  A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study.

Authors:  Yumiko Akagi-Kurashige; Akitaka Tsujikawa; Mitsuko Yuzawa; Tatsuro Ishibashi; Hideo Nakanishi; Eiji Nakatani; Satoshi Teramukai; Masanori Fukushima; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2017-12-09       Impact factor: 2.447

5.  Visual outcomes of vitrectomy for polypoidal choroidal vasculopathy-related breakthrough vitreous haemorrhage.

Authors:  H-C Lin; C-H Yang; C-M Yang
Journal:  Eye (Lond)       Date:  2014-06-13       Impact factor: 3.775

6.  Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Shunichiro Nakai; Wataru Matsumiya; Akiko Miki; Shigeru Honda; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2019-08-02       Impact factor: 2.447

7.  Two-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  Masayuki Hata; Akitaka Tsujikawa; Masahiro Miyake; Kenji Yamashiro; Sotaro Ooto; Akio Oishi; Hideo Nakanishi; Ayako Takahashi; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-25       Impact factor: 3.117

Review 8.  Genetic associations in polypoidal choroidal vasculopathy: a systematic review and meta-analysis.

Authors:  Haoyu Chen; Ke Liu; Li Jia Chen; Ping Hou; Weiqi Chen; Chi Pui Pang
Journal:  Mol Vis       Date:  2012-04-04       Impact factor: 2.367

Review 9.  Polypoidal Choroidal Vasculopathy in Asians.

Authors:  Chee Wai Wong; Tien Y Wong; Chui Ming Gemmy Cheung
Journal:  J Clin Med       Date:  2015-04-24       Impact factor: 4.241

10.  Management of significant reactivation of old disciform scars in wet age-related macular degeneration.

Authors:  Rosa M Coco; Anna Sala-Puigdollers
Journal:  BMC Ophthalmol       Date:  2014-06-25       Impact factor: 2.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.